{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T02:01:39Z","timestamp":1776909699243,"version":"3.51.2"},"reference-count":35,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Background\/Objectives: Gaucher disease (GD) is a lysosomal disorder caused by a deficiency of \u03b2-glucosidase. Disease-modifying therapies (DMTs) include enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). Glucosylsphingosine (lyso-Gb1) is a biomarker with high sensitivity and specificity in GD. Methods: In GD patients attending a specialist centre, we evaluated dried blood spot lyso-Gb1 levels (normal values \u2264 6.8 ng\/mL) by treatment status, sex, GD type and genotype, ERT dose, DMT type and duration, spleen status, and association with other GD biomarkers. Results: A total of 111 patients were screened; 100 (54M:46F; 93 GD1 and 7 GD3; median age 45.2 years, IQR 34.2\u201357.2; 7 naive and 93 patients on DMTs for a median of 10.4 years, IQR 5.7\u201321.2) had at least one lyso-Gb1 measurement. Median lyso-Gb1 values were higher in na\u00efve (195, IQR 48.6\u2013388) patients than treated patients (47.1, IQR 23.1\u201389.7), p = 0.015; higher in those treated \u2265 15 years (62.9, IQR 36.6\u2013103) than in those treated &lt; 15 years (35.1, IQR 20.3\u201373.9), p = 0.006; and higher in splenectomised (83.4, IQR 34.7\u2013224.5) patients than non-splenectomised patients (40.7, IQR 21.4\u201377.1), p = 0.044. ERT dose &gt; 60 U\/kg had high median lyso-Gb1 values (87.3, IQR 19.7\u2013126), reflecting greater disease burden, and this high dose was only used in patients with GD3. Lyso-Gb1 correlated with chitotriosidase (r = 0.495; p &lt; 0.001) and haemoglobin (r = \u22120.231; p = 0.022). In a subset of 50 patients with paired values, lyso-Gb1 decreased from baseline (median \u22121.7 ng\/mL, IQR \u221224.5\u201314.8). Conclusions: Whilst there was a modest decrease in lyso-Gb1 over time on DMTs, the values remained significantly above the normal range, which may be driven by underlying mechanisms such as inflammation.<\/jats:p>","DOI":"10.3390\/metabo15110731","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:41:47Z","timestamp":1762515707000},"page":"731","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gaucher Disease\u2014Correlation of Lyso-Gb1 with Haematology and Biochemical Parameters"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5432-8808","authenticated-orcid":false,"given":"Simona","family":"D\u2019Amore","sequence":"first","affiliation":[{"name":"Lysosomal Storage Disorders Unit, Royal Free Hospital NHS Foundation Trust London, London NW3 2QG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha","family":"Patel","sequence":"additional","affiliation":[{"name":"Lysosomal Storage Disorders Unit, Royal Free Hospital NHS Foundation Trust London, London NW3 2QG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juniebel","family":"Cooke","sequence":"additional","affiliation":[{"name":"Lysosomal Storage Disorders Unit, Royal Free Hospital NHS Foundation Trust London, London NW3 2QG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4703-7447","authenticated-orcid":false,"given":"Uma","family":"Ramaswami","sequence":"additional","affiliation":[{"name":"Lysosomal Storage Disorders Unit, Royal Free Hospital NHS Foundation Trust London, London NW3 2QG, UK"},{"name":"Genetics and Genomic Medicine, University College London, London WC1N 1EH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"ref_1","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993). Gaucher Disease, in GeneReviews((R)), University of Washington."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher\u2019s disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"ref_3","unstructured":"Valle, D.B., Beaudet, A.L., Vogelstein, B., Kinzler, K.W., Antonarakis, S.E., Ballabio, A., Gibson, K., and Mitchell, G.A. (2013). Gaucher Disease in the Online Metabolic and Molecular Bases of Inherited Disease. McGrawHill."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: Formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s13023-021-02034-6","article-title":"In-depth phenotyping for clinical stratification of Gaucher disease","volume":"16","author":"Page","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"D\u2019Amore, S., Poole, K.E., Ramaswami, U., Hughes, D., Page, K., Solimando, A.G., Vacca, A., Cox, T.M., and Deegan, P. (2024). Changes in Angiogenesis and Bone Turnover Markers in Patients with Gaucher Disease Developing Osteonecrosis. Metabolites, 14.","DOI":"10.3390\/metabo14110601"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","article-title":"Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease","volume":"68","author":"Biegstraaten","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ymgme.2016.12.001","article-title":"Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry","volume":"120","author":"Vellodi","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ymgme.2014.07.022","article-title":"Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients","volume":"113","author":"Sechi","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00256-014-1891-9","article-title":"Skeletal improvement in patients with Gaucher disease type 1: A phase 2 trial of oral eliglustat","volume":"43","author":"Kamath","year":"2014","journal-title":"Skeletal. Radiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: A phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: The ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","article-title":"Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy","volume":"129","author":"Cox","year":"2017","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100329","DOI":"10.1016\/j.gim.2022.10.011","article-title":"Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1","volume":"25","author":"Cox","year":"2023","journal-title":"Genet. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.1779","article-title":"Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme","volume":"18","author":"Hollak","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bcmd.2016.10.017","article-title":"Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project","volume":"68","author":"Giraldo","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1515\/CCLM.2002.010","article-title":"Relationships between serum markers of monocyte\/macrophage activation in type 1 Gaucher\u2019s disease","volume":"40","author":"Casal","year":"2002","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cccn.2004.02.018","article-title":"Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy","volume":"344","author":"Henderson","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0950-3536(97)80034-0","article-title":"Plasma and metabolic abnormalities in Gaucher\u2019s disease","volume":"10","author":"Aerts","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"25680","DOI":"10.1074\/jbc.273.40.25680","article-title":"The human chitotriosidase gene. Nature of inherited enzyme deficiency","volume":"273","author":"Boot","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.bcmd.2004.07.005","article-title":"Allelic frequency determination of the 24-bp chitotriosidase duplication in the Portuguese population by real-time PCR","volume":"33","author":"Rodrigues","year":"2004","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: Relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Rolfs, A., Giese, A.K., Grittner, U., Mascher, D., Elstein, D., Zimran, A., B\u00f6ttcher, T., Lukas, J., H\u00fcbner, R., and G\u00f6lnitz, U. (2013). Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079732"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13023-024-03444-y","article-title":"Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey","volume":"20","author":"Zimran","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Cozma, C., Cullufi, P., Kramp, G., Hovakimyan, M., Velmishi, V., Gjikopulli, A., Tomori, S., Fischer, S., Oppermann, S., and Grittner, U. (2020). Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134577"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ymgme.2007.05.013","article-title":"The outcome of clinical parameters in adults with severe Type I Gaucher disease using very low dose enzyme replacement therapy","volume":"92","author":"Wilson","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s10545-009-1164-2","article-title":"Management of neuronopathic Gaucher disease: Revised recommendations","volume":"32","author":"Vellodi","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/jimd.12192","article-title":"Expanding the clinical utility of glucosylsphingosine for Gaucher disease","volume":"43","author":"Saville","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Dinur, T., Bauer, P., Beetz, C., Cozma, C., Becker-Cohen, M., Istaiti, M., Rolfs, A., Skrahina, V., Zimran, A., and Revel-Vilk, S. (2023). Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043945"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/pd.2584","article-title":"Sixteen years of prenatal consultations for the N370S\/N370S Gaucher disease genotype: What have we learned?","volume":"30","author":"Eitan","year":"2010","journal-title":"Prenat. Diagn."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Dinur, T., Grittner, U., Revel-Vilk, S., Becker-Cohen, M., Istaiti, M., Cozma, C., Rolfs, A., and Zimran, A. (2021). Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147699"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ivanova, M.M., Dao, J., Kasaci, N., Huang, F., Nguyen, E., and Goker-Alpan, O. (2025). Age-related inflammatory biomarkers in early-onset osteoporosis in females with Gaucher disease. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1606218"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"108694","DOI":"10.1016\/j.ymgme.2024.108694","article-title":"Gaucher disease\u2013correlation of lyso-Gb1 with biochemical therapeutic goals","volume":"144","author":"Cooke","year":"2025","journal-title":"Mol. Genet. Metab."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/15\/11\/731\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:59:09Z","timestamp":1762516749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/15\/11\/731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["metabo15110731"],"URL":"https:\/\/doi.org\/10.3390\/metabo15110731","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]}}}